← Leaderboards
Alison Oliveto Beaudoin
Yale University
$13,435,140
Attributed
$14,869,284
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$14,869,284 · 12
By mechanism
R01$10,111,549 · 5
P50$3,562,108 · 3
R21$1,187,462 · 3
M01$8,165 · 1
Top collaborators
- Michael J Mancino5 shared
Most similar at Yale University
Same institution · by research overlap
- Elinore F. McCance-Katz$13,032,111
- Robert T Malison$17,226,399
- Gustavo Adolfo Angarita$6,671,858
Others in their field
Top investigators on “Placebos”
- Beth Baseler · Leidos Biomedical Research, Inc.$141,816,521
- Randall J Bateman · Washington University$134,290,222
- Elizabeth A Thom · George Washington University$115,751,620
- Eric Martin McDade · Washington University$96,859,497
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$93,253,804
- Georgia D Tomaras · Fred Hutchinson Cancer Center$93,253,804
Research focus
PlacebosPharmaceutical PreparationsClinical TrialsCocaineRelative (Related Person)Patient Self-ReportParticipantMethadoneRandomizedTreatment OutcomeWithdrawalHuman SubjectProgramsClinical ResearchOpioidSeveritiesUrinalysisRelapseDrug AddictionPsychosocialDopaminePharmacotherapyResponseDouble-Blind Method
Grant awards (47)
Improving Treatment Outcomes for Prescription Opioid Dependence$537,833
R01 · FY2019 · DA · contact PI
Improving Treatment Outcomes for Prescription Opioid Dependence$578,697
R01 · FY2018 · DA · contact PI
Improving Treatment Outcomes for Prescription Opioid Dependence$578,697
R01 · FY2017 · DA · contact PI
Improving Treatment Outcomes for Prescription Opioid Dependence$572,912
R01 · FY2016 · DA · contact PI
Improving Treatment Outcomes for Prescription Opioid Dependence$600,150
R01 · FY2015 · DA · contact PI
Improving Buprenorphine Detoxification Outcomes with Isradipine$184,375
R21 · FY2014 · DA · contact PI
Carvedilol Studies$422,617
P50 · FY2013 · DA · contact PI
Improving Buprenorphine Detoxification Outcomes with Isradipine$221,250
R21 · FY2013 · DA · contact PI
Impact CYP2D6 Phenotype on Response to Methamphetamine in Humans$201,780
R21 · FY2013 · DA · contact PI
Carvedilol Studies$396,460
P50 · FY2012 · DA · contact PI
Clinical Efficacy of Atomoxetine for Methamphetamine Dependence$221,250
R21 · FY2012 · DA · contact PI
Impact CYP2D6 Phenotype on Response to Methamphetamine in Humans$175,057
R21 · FY2012 · DA · contact PI
Carvedilol Studies$342,489
P50 · FY2011 · DA · contact PI
Opioid Antagonist Discrimination: A Model of Withdrawal$291,961
R01 · FY2011 · DA · contact PI
Clinical Efficacy of Atomoxetine for Methamphetamine Dependence$183,750
R21 · FY2011 · DA · contact PI
Disulfiram for Cocaine Abuse in Metadone - Patients$552,837
R01 · FY2010 · DA · contact PI
Carvedilol Studies$379,505
P50 · FY2010 · DA · contact PI
Opioid Antagonist Discrimination: A Model of Withdrawal$300,990
R01 · FY2010 · DA · contact PI
Disulfiram for Cocaine Abuse in Methadone - Patients$588,265
R01 · FY2009 · DA · contact PI
Carvedilol Studies$400,228
P50 · FY2009 · DA · contact PI
Disulfiram for Cocaine Abuse in Methadone - Patients$573,143
R01 · FY2008 · DA · contact PI
Opioid Antagonist Discrimination: A Model of Withdrawal$337,811
R01 · FY2008 · DA · contact PI
Sertraline Augmentation for Cocaine Dependence$327,393
P50 · FY2008 · DA · contact PI
Disulfiram for Cocaine Abuse in Methadone - Patients$569,847
R01 · FY2007 · DA · contact PI
Sertraline Augmentation for Cocaine Dependence$344,816
P50 · FY2007 · DA · contact PI
Opioid Antagonist Discrimination: A Model of Withdrawal$336,604
R01 · FY2007 · DA · contact PI
Disulfiram for Cocaine Abuse in Metadone - Patients$561,063
R01 · FY2006 · DA · contact PI
Opioid Antagonist Discrimination: A Model of Withdrawal$355,000
R01 · FY2006 · DA · contact PI
Sertraline Augmentation for Cocaine Dependence$271,217
P50 · FY2006 · DA · contact PI
THE DISCRIMINATIVE STIMULUS, SELF-REPORTED AND PHYSIOLOGICAL EFFECTS OF COMMON M$8,165
M01 · FY2006 · RR · contact PI
Disulfiram for Cocaine Abuse in Methadone- Patients$340,455
R01 · FY2005 · DA
Sertraline Augmentation for Cocaine Dependence$265,276
P50 · FY2005 · DA
Sertraline Augmentation for Cocaine Dependence$251,357
P50 · FY2004 · DA
Disulfiram for Cocaine Abuse in Methadone- Patients$241,342
R01 · FY2004 · DA
Disulfiram for Cocaine Abuse in Methadone- Patients$111,233
R01 · FY2004 · DA
Disulfiram for Cocaine Abuse in Methadone- Patients$354,601
R01 · FY2003 · DA
Behavioral Effects of GHB in Healthy Volunteers$167,639
R01 · FY2003 · DA
Behavioral Effects of GHB in Healthy Volunteers$49,861
R01 · FY2003 · DA
Disulfiram for Cocaine Abuse in Methadone- Patients$354,751
R01 · FY2002 · DA
Behavioral Effects of GHB in Healthy Volunteers$217,500
R01 · FY2002 · DA
ANTIDEPRESSANT TREATMENT FOR DEPRESSED COCAINE DEPENDENT PATIENTS$0
P50 · FY2002 · DA
Disulfiram for Cocaine Abuse in Methadone- Patients$356,803
R01 · FY2001 · DA
Behavioral Effects of GHB in Healthy Volunteers$215,905
R01 · FY2001 · DA
ANTIDEPRESSANT TREATMENT FOR DEPRESSED COCAINE DEPENDENT PATIENTS$0
P50 · FY2001 · DA
OPIOID ANTAGONIST DISCRIMINATION--A MODEL OF WITHDRAWAL$202,134
R01 · FY2000 · DA
LAAM WITH BEHAVIORAL TREATMENT FOR OPIOID/COCAINE ABUSE$163,515
R01 · FY2000 · DA
ANTIDEPRESSANT TREATMENT FOR DEPRESSED COCAINE DEPENDENT PATIENTS$160,750
P50 · FY2000 · DA